Trial Profile
Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Etoposide; Isotretinoin
- Indications Neuroblastoma
- Focus Therapeutic Use
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.